Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Core Points - Valneva SE, a specialty vaccine company, filed its 2024 Universal Registration Document with the French Financial Markets Authority and its Form 20-F with the U.S. Securities and Exchange Commission on March 24, 2025 [1] - The 2024 Universal Registration Document includes the Company's Annual Financial Report, Annual Management Report, Corporate Governance Report, and Sustainability Statement [2] - These documents are accessible on Valneva's website and will also be available on the AMF and SEC websites [3] Company Overview - Valneva SE focuses on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [4] - The company has successfully advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines, including the world's first chikungunya vaccine [5] - Revenues from the commercial business support the advancement of the vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development partnered with Pfizer and the most clinically advanced Shigella vaccine candidate [6]